Investor Alert: Upcoming Deadlines in Shareholder Litigation Involving Vical Incorporated and Amarin Corporation plc

Marketwired

ATLANTA, GA--(Marketwired - Nov 6, 2013) - Holzer Holzer & Fistel LLC reminds investors of upcoming deadlines for applications to serve as lead plaintiff in securities class action lawsuits against Vical Incorporated and Amarin Corp. plc.

Investors that suffered significant losses investing in either of these companies during the specified times who are interested in potentially serving as lead plaintiff in the respective class actions are encouraged to contact Michael I. Fistel, Jr., Esq. (mfistel@holzerlaw.com) or Marshall P. Dees, Esq. (mdees@holzerlaw.com) by email or via toll-free telephone at (888) 508-6832 to discuss their legal rights.

A lead plaintiff is a representative party appointed by the court to act on behalf of other class members in directing the litigation. Any member of the purported class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Vical Inc.

A class action lawsuit has been filed on behalf of investors who purchased Vical (NASDAQ: VICL) securities between February 8, 2012 and August 12, 2013. The lawsuit alleges the company violated the federal securities laws by allegedly misleading investors as to the efficacy and likely success of the company's Phase 3 trial for its drug Allovectin. 

The deadline to seek appointment as lead plaintiff in this lawsuit, which is pending in the United States District Court for the Southern District of California, is December 31, 2013. More information about the lawsuit and the firm are available at www.holzerlaw.com.

Amarin Corp. plc

A class action lawsuit has been filed on behalf of investors who purchased Amarin (NASDAQ: AMRN) securities between July 9, 2009 and October 15, 2013, alleging the company violated the federal securities laws by, among other things, misrepresenting the prospects that its experimental drug Vascepa would receive approval from the U.S. Food and Drug Administration.

The deadline to seek appointment as lead plaintiff in this lawsuit, which is pending in the United States District Court for the District of New Jersey, is January 3, 2014. More information about the lawsuit and the firm are available at www.holzerlaw.com.

About The Firm

Holzer Holzer & Fistel, LLC dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com. and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content

Rates

View Comments (0)